Zunaira Mallick

Zunaira joined Eradigm in March 2022 as an Associate Consultant. With a passion to increase healthcare accessibility, she brings extensive academic and commercial experience from working globally across both public and private healthcare spaces.  

Zunaira has previously delivered competitive market strategy projects spanning multiple disease areas including gastroenterology, haematology, immunology, psychiatry, and rare diseases. Having worked at a health strategy firm with global, EU and UK product teams for the top 20 pharma companies, she has developed expertise in liaising with key stakeholders to identify areas of growth across the entire drug lifecycle, from pre-clinical development to go-to-market (GMT) strategies for new entrants including CAR-T therapy in multiple myeloma. In addition, she has extensively conducted primary and secondary research to monitor and assess competitive landscapes in cell and antibody-based therapies within the wider pharmaceutical industry. She has also worked with regulatory bodies and pharma product managers on developing health technology assessment (HTA) strategies for a medical device used to treat depression, with a focus towards evaluating patient-centric, value-driven evidence. 

Prior to this, Zunaira has conducted comprehensive research in the public healthcare sector, first as a policy analyst developing tactical recommendations on improving patient access to primary care medical facilities in South Asia, followed by her work leading educational workshops for a global rheumatic heart disease clinical trial. 

Zunaira completed her MSc from the University of Oxford in Integrated Immunology, graduating top three in her year. Her thesis was focused on developing a Point-of-Care (PoC) diagnostic test for immune profiling sepsis patients in intensive care settings. In this project, she successfully used host transcriptomics data to identify differentially expressed genes for subgrouping patients and was then able to develop a PCR-based technique for testing patient samples which proved to be 99.1% diagnostically accurate. As part of the project, she also comprehensively conducted due diligence on different sequencing technologies for the purpose of setting up a commercial diagnostic test. This test was later used to effectively immune profile septic COVID-19 patients as part of the extended research study at the Wellcome Trust for Human Genetics. 

Zunaira holds a BSc (Honours) in Biomedical Sciences from the University of Waterloo, where she graduated Summa Cum Laude and was one of seven students in the entire Faculty of Science to win the National Science and Engineering Research Council (NSERC) Award for excellence in research focusing on characterising a novel bacterium. 

In her spare time, Zunaira likes to brainstorm ideas for AI-enabled initiatives that are aimed at improving patient care pathways. She also likes to read historical non-fiction and poetry. In addition, she is an avid art (poster) collector, always on the hunt for exhibitions featuring surrealist, abstract expressionist, and post-impressionist artworks. In sports, she enjoys playing badminton and tennis, and has previously swam and rowed competitively in school and at university respectively.